nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—CYP1A2—Clobetasol propionate—psoriasis	0.23	0.459	CbGbCtD
Agomelatine—CYP1A2—Methoxsalen—psoriasis	0.121	0.241	CbGbCtD
Agomelatine—CYP2C9—Cholecalciferol—psoriasis	0.0722	0.144	CbGbCtD
Agomelatine—CYP2C9—Cyclosporine—psoriasis	0.0475	0.0945	CbGbCtD
Agomelatine—CYP2C9—Dexamethasone—psoriasis	0.0313	0.0622	CbGbCtD
Agomelatine—Indomethacin—CXCL8—psoriasis	0.00376	0.591	CrCbGaD
Agomelatine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00275	0.0587	CbGpPWpGaD
Agomelatine—Indomethacin—PPARG—psoriasis	0.0026	0.409	CrCbGaD
Agomelatine—MTNR1B—G alpha (i) signalling events—HCAR2—psoriasis	0.00198	0.0421	CbGpPWpGaD
Agomelatine—MTNR1A—G alpha (i) signalling events—HCAR2—psoriasis	0.00198	0.0421	CbGpPWpGaD
Agomelatine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.0017	0.0364	CbGpPWpGaD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00157	0.0335	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00157	0.0335	CbGpPWpGaD
Agomelatine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00146	0.0311	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—HCAR2—psoriasis	0.0012	0.0255	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—HCAR2—psoriasis	0.0012	0.0255	CbGpPWpGaD
Agomelatine—MTNR1B—G alpha (i) signalling events—CCL20—psoriasis	0.00103	0.0219	CbGpPWpGaD
Agomelatine—MTNR1A—G alpha (i) signalling events—CCL20—psoriasis	0.00103	0.0219	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000816	0.0174	CbGpPWpGaD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000816	0.0174	CbGpPWpGaD
Agomelatine—Skin disorder—Mycophenolic acid—psoriasis	0.000786	0.00177	CcSEcCtD
Agomelatine—Vomiting—Acitretin—psoriasis	0.000783	0.00176	CcSEcCtD
Agomelatine—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000783	0.00176	CcSEcCtD
Agomelatine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000781	0.00176	CcSEcCtD
Agomelatine—Headache—Acitretin—psoriasis	0.000771	0.00174	CcSEcCtD
Agomelatine—Headache—Fluocinolone Acetonide—psoriasis	0.000769	0.00173	CcSEcCtD
Agomelatine—Eye disorder—Hydrocortisone—psoriasis	0.000766	0.00172	CcSEcCtD
Agomelatine—Back pain—Mycophenolate mofetil—psoriasis	0.000757	0.0017	CcSEcCtD
Agomelatine—Vision blurred—Cyclosporine—psoriasis	0.000756	0.0017	CcSEcCtD
Agomelatine—Tremor—Cyclosporine—psoriasis	0.000752	0.00169	CcSEcCtD
Agomelatine—Agitation—Cyclosporine—psoriasis	0.000737	0.00166	CcSEcCtD
Agomelatine—Tremor—Mycophenolate mofetil—psoriasis	0.000733	0.00165	CcSEcCtD
Agomelatine—Angioedema—Cyclosporine—psoriasis	0.000733	0.00165	CcSEcCtD
Agomelatine—Insomnia—Mycophenolic acid—psoriasis	0.000732	0.00165	CcSEcCtD
Agomelatine—Nausea—Acitretin—psoriasis	0.000731	0.00165	CcSEcCtD
Agomelatine—Nausea—Fluocinolone Acetonide—psoriasis	0.000729	0.00164	CcSEcCtD
Agomelatine—Paraesthesia—Mycophenolic acid—psoriasis	0.000727	0.00164	CcSEcCtD
Agomelatine—Vertigo—Cyclosporine—psoriasis	0.000721	0.00162	CcSEcCtD
Agomelatine—Somnolence—Mycophenolic acid—psoriasis	0.00072	0.00162	CcSEcCtD
Agomelatine—Agitation—Mycophenolate mofetil—psoriasis	0.000719	0.00162	CcSEcCtD
Agomelatine—Mental disorder—Hydrocortisone—psoriasis	0.000718	0.00162	CcSEcCtD
Agomelatine—Angioedema—Mycophenolate mofetil—psoriasis	0.000715	0.00161	CcSEcCtD
Agomelatine—Dyspepsia—Mycophenolic acid—psoriasis	0.000713	0.0016	CcSEcCtD
Agomelatine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000708	0.0151	CbGpPWpGaD
Agomelatine—Vertigo—Mycophenolate mofetil—psoriasis	0.000703	0.00158	CcSEcCtD
Agomelatine—Irritability—Methotrexate—psoriasis	0.000703	0.00158	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000699	0.00157	CcSEcCtD
Agomelatine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000699	0.0149	CbGpPWpGaD
Agomelatine—Fatigue—Mycophenolic acid—psoriasis	0.000698	0.00157	CcSEcCtD
Agomelatine—Hallucination—Dexamethasone—psoriasis	0.000696	0.00157	CcSEcCtD
Agomelatine—Hallucination—Betamethasone—psoriasis	0.000696	0.00157	CcSEcCtD
Agomelatine—Asthenia—Hydroxyurea—psoriasis	0.000693	0.00156	CcSEcCtD
Agomelatine—Weight increased—Prednisone—psoriasis	0.000693	0.00156	CcSEcCtD
Agomelatine—Constipation—Mycophenolic acid—psoriasis	0.000692	0.00156	CcSEcCtD
Agomelatine—Weight decreased—Prednisone—psoriasis	0.000689	0.00155	CcSEcCtD
Agomelatine—Vision blurred—Prednisolone—psoriasis	0.000688	0.00155	CcSEcCtD
Agomelatine—Anxiety—Cyclosporine—psoriasis	0.000681	0.00153	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000678	0.00153	CcSEcCtD
Agomelatine—Depression—Prednisone—psoriasis	0.000677	0.00152	CcSEcCtD
Agomelatine—MTNR1A—GPCR downstream signaling—HCAR2—psoriasis	0.000676	0.0144	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—HCAR2—psoriasis	0.000676	0.0144	CbGpPWpGaD
Agomelatine—Dry mouth—Cyclosporine—psoriasis	0.000668	0.0015	CcSEcCtD
Agomelatine—Angioedema—Prednisolone—psoriasis	0.000667	0.0015	CcSEcCtD
Agomelatine—Anxiety—Mycophenolate mofetil—psoriasis	0.000664	0.00149	CcSEcCtD
Agomelatine—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000662	0.00149	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000662	0.00149	CcSEcCtD
Agomelatine—Diarrhoea—Hydroxyurea—psoriasis	0.000661	0.00149	CcSEcCtD
Agomelatine—Vertigo—Prednisolone—psoriasis	0.000656	0.00148	CcSEcCtD
Agomelatine—Eye disorder—Betamethasone—psoriasis	0.000654	0.00147	CcSEcCtD
Agomelatine—Eye disorder—Dexamethasone—psoriasis	0.000654	0.00147	CcSEcCtD
Agomelatine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000652	0.00147	CcSEcCtD
Agomelatine—Angioedema—Hydrocortisone—psoriasis	0.000652	0.00147	CcSEcCtD
Agomelatine—Infection—Cyclosporine—psoriasis	0.000651	0.00146	CcSEcCtD
Agomelatine—Back pain—Triamcinolone—psoriasis	0.00065	0.00146	CcSEcCtD
Agomelatine—Nervous system disorder—Cyclosporine—psoriasis	0.000642	0.00145	CcSEcCtD
Agomelatine—Vertigo—Hydrocortisone—psoriasis	0.000641	0.00144	CcSEcCtD
Agomelatine—Abdominal pain—Mycophenolic acid—psoriasis	0.00064	0.00144	CcSEcCtD
Agomelatine—Dizziness—Hydroxyurea—psoriasis	0.000639	0.00144	CcSEcCtD
Agomelatine—Skin disorder—Cyclosporine—psoriasis	0.000636	0.00143	CcSEcCtD
Agomelatine—Infection—Mycophenolate mofetil—psoriasis	0.000635	0.00143	CcSEcCtD
Agomelatine—Hyperhidrosis—Cyclosporine—psoriasis	0.000633	0.00142	CcSEcCtD
Agomelatine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000626	0.00141	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—CCL20—psoriasis	0.000621	0.0133	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—CCL20—psoriasis	0.000621	0.0133	CbGpPWpGaD
Agomelatine—Skin disorder—Mycophenolate mofetil—psoriasis	0.000621	0.0014	CcSEcCtD
Agomelatine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000618	0.00139	CcSEcCtD
Agomelatine—Vomiting—Hydroxyurea—psoriasis	0.000615	0.00138	CcSEcCtD
Agomelatine—MTNR1B—Signaling by GPCR—HCAR2—psoriasis	0.000614	0.0131	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HCAR2—psoriasis	0.000614	0.0131	CbGpPWpGaD
Agomelatine—Angioedema—Triamcinolone—psoriasis	0.000614	0.00138	CcSEcCtD
Agomelatine—Hallucination—Prednisone—psoriasis	0.000606	0.00136	CcSEcCtD
Agomelatine—Headache—Hydroxyurea—psoriasis	0.000605	0.00136	CcSEcCtD
Agomelatine—Anxiety—Hydrocortisone—psoriasis	0.000605	0.00136	CcSEcCtD
Agomelatine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000605	0.0129	CbGpPWpGaD
Agomelatine—Vertigo—Triamcinolone—psoriasis	0.000603	0.00136	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000603	0.00136	CcSEcCtD
Agomelatine—Connective tissue disorder—Prednisone—psoriasis	0.000599	0.00135	CcSEcCtD
Agomelatine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000597	0.0127	CbGpPWpGaD
Agomelatine—Insomnia—Cyclosporine—psoriasis	0.000592	0.00133	CcSEcCtD
Agomelatine—Paraesthesia—Cyclosporine—psoriasis	0.000588	0.00132	CcSEcCtD
Agomelatine—Somnolence—Cyclosporine—psoriasis	0.000582	0.00131	CcSEcCtD
Agomelatine—Asthenia—Mycophenolic acid—psoriasis	0.000581	0.00131	CcSEcCtD
Agomelatine—Infection—Hydrocortisone—psoriasis	0.000578	0.0013	CcSEcCtD
Agomelatine—Insomnia—Mycophenolate mofetil—psoriasis	0.000578	0.0013	CcSEcCtD
Agomelatine—Dyspepsia—Cyclosporine—psoriasis	0.000576	0.0013	CcSEcCtD
Agomelatine—Hyperhidrosis—Prednisolone—psoriasis	0.000576	0.0013	CcSEcCtD
Agomelatine—Nausea—Hydroxyurea—psoriasis	0.000574	0.00129	CcSEcCtD
Agomelatine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000574	0.0122	CbGpPWpGaD
Agomelatine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000574	0.00129	CcSEcCtD
Agomelatine—Pruritus—Mycophenolic acid—psoriasis	0.000573	0.00129	CcSEcCtD
Agomelatine—Nervous system disorder—Hydrocortisone—psoriasis	0.000571	0.00128	CcSEcCtD
Agomelatine—Eye disorder—Prednisone—psoriasis	0.00057	0.00128	CcSEcCtD
Agomelatine—Somnolence—Mycophenolate mofetil—psoriasis	0.000568	0.00128	CcSEcCtD
Agomelatine—Infestation NOS—Methotrexate—psoriasis	0.000567	0.00128	CcSEcCtD
Agomelatine—Infestation—Methotrexate—psoriasis	0.000567	0.00128	CcSEcCtD
Agomelatine—Depression—Methotrexate—psoriasis	0.000566	0.00127	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000565	0.00127	CcSEcCtD
Agomelatine—Skin disorder—Hydrocortisone—psoriasis	0.000565	0.00127	CcSEcCtD
Agomelatine—Fatigue—Cyclosporine—psoriasis	0.000565	0.00127	CcSEcCtD
Agomelatine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000563	0.00127	CcSEcCtD
Agomelatine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000562	0.00127	CcSEcCtD
Agomelatine—Constipation—Cyclosporine—psoriasis	0.00056	0.00126	CcSEcCtD
Agomelatine—Dry mouth—Triamcinolone—psoriasis	0.000559	0.00126	CcSEcCtD
Agomelatine—Angioedema—Dexamethasone—psoriasis	0.000557	0.00125	CcSEcCtD
Agomelatine—Angioedema—Betamethasone—psoriasis	0.000557	0.00125	CcSEcCtD
Agomelatine—Diarrhoea—Mycophenolic acid—psoriasis	0.000554	0.00125	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000552	0.00124	CcSEcCtD
Agomelatine—Vertigo—Betamethasone—psoriasis	0.000547	0.00123	CcSEcCtD
Agomelatine—Vertigo—Dexamethasone—psoriasis	0.000547	0.00123	CcSEcCtD
Agomelatine—Constipation—Mycophenolate mofetil—psoriasis	0.000546	0.00123	CcSEcCtD
Agomelatine—Infection—Triamcinolone—psoriasis	0.000544	0.00123	CcSEcCtD
Agomelatine—Insomnia—Prednisolone—psoriasis	0.000539	0.00121	CcSEcCtD
Agomelatine—Hepatobiliary disease—Methotrexate—psoriasis	0.000537	0.00121	CcSEcCtD
Agomelatine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000535	0.00121	CcSEcCtD
Agomelatine—Dizziness—Mycophenolic acid—psoriasis	0.000535	0.0012	CcSEcCtD
Agomelatine—Paraesthesia—Prednisolone—psoriasis	0.000535	0.0012	CcSEcCtD
Agomelatine—Mental disorder—Prednisone—psoriasis	0.000534	0.0012	CcSEcCtD
Agomelatine—Hyperhidrosis—Triamcinolone—psoriasis	0.00053	0.00119	CcSEcCtD
Agomelatine—Insomnia—Hydrocortisone—psoriasis	0.000526	0.00118	CcSEcCtD
Agomelatine—Paraesthesia—Hydrocortisone—psoriasis	0.000523	0.00118	CcSEcCtD
Agomelatine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000522	0.00118	CcSEcCtD
Agomelatine—Urticaria—Cyclosporine—psoriasis	0.00052	0.00117	CcSEcCtD
Agomelatine—Abdominal pain—Cyclosporine—psoriasis	0.000518	0.00117	CcSEcCtD
Agomelatine—Anxiety—Betamethasone—psoriasis	0.000517	0.00116	CcSEcCtD
Agomelatine—Anxiety—Dexamethasone—psoriasis	0.000517	0.00116	CcSEcCtD
Agomelatine—Vomiting—Mycophenolic acid—psoriasis	0.000515	0.00116	CcSEcCtD
Agomelatine—Dyspepsia—Hydrocortisone—psoriasis	0.000512	0.00115	CcSEcCtD
Agomelatine—Hepatitis—Methotrexate—psoriasis	0.000509	0.00115	CcSEcCtD
Agomelatine—Urticaria—Mycophenolate mofetil—psoriasis	0.000507	0.00114	CcSEcCtD
Agomelatine—Headache—Mycophenolic acid—psoriasis	0.000507	0.00114	CcSEcCtD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000507	0.0108	CbGpPWpGaD
Agomelatine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000505	0.00114	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000502	0.00113	CcSEcCtD
Agomelatine—Fatigue—Hydrocortisone—psoriasis	0.000502	0.00113	CcSEcCtD
Agomelatine—Vision blurred—Prednisone—psoriasis	0.0005	0.00113	CcSEcCtD
Agomelatine—Insomnia—Triamcinolone—psoriasis	0.000496	0.00112	CcSEcCtD
Agomelatine—Infection—Dexamethasone—psoriasis	0.000494	0.00111	CcSEcCtD
Agomelatine—Infection—Betamethasone—psoriasis	0.000494	0.00111	CcSEcCtD
Agomelatine—Paraesthesia—Triamcinolone—psoriasis	0.000492	0.00111	CcSEcCtD
Agomelatine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00049	0.0105	CbGpPWpGaD
Agomelatine—Nervous system disorder—Betamethasone—psoriasis	0.000488	0.0011	CcSEcCtD
Agomelatine—Nervous system disorder—Dexamethasone—psoriasis	0.000488	0.0011	CcSEcCtD
Agomelatine—Agitation—Prednisone—psoriasis	0.000488	0.0011	CcSEcCtD
Agomelatine—Angioedema—Prednisone—psoriasis	0.000485	0.00109	CcSEcCtD
Agomelatine—Dyspepsia—Triamcinolone—psoriasis	0.000482	0.00109	CcSEcCtD
Agomelatine—Nausea—Mycophenolic acid—psoriasis	0.000481	0.00108	CcSEcCtD
Agomelatine—Hyperhidrosis—Betamethasone—psoriasis	0.000481	0.00108	CcSEcCtD
Agomelatine—Hyperhidrosis—Dexamethasone—psoriasis	0.000481	0.00108	CcSEcCtD
Agomelatine—Vertigo—Prednisone—psoriasis	0.000477	0.00107	CcSEcCtD
Agomelatine—Eye disorder—Methotrexate—psoriasis	0.000476	0.00107	CcSEcCtD
Agomelatine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000476	0.00107	CcSEcCtD
Agomelatine—Tinnitus—Methotrexate—psoriasis	0.000475	0.00107	CcSEcCtD
Agomelatine—Urticaria—Prednisolone—psoriasis	0.000473	0.00107	CcSEcCtD
Agomelatine—MTNR1A—Circadian rythm related genes—LEP—psoriasis	0.000472	0.0101	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—LEP—psoriasis	0.000472	0.0101	CbGpPWpGaD
Agomelatine—Fatigue—Triamcinolone—psoriasis	0.000472	0.00106	CcSEcCtD
Agomelatine—Asthenia—Cyclosporine—psoriasis	0.00047	0.00106	CcSEcCtD
Agomelatine—Pruritus—Cyclosporine—psoriasis	0.000463	0.00104	CcSEcCtD
Agomelatine—Urticaria—Hydrocortisone—psoriasis	0.000462	0.00104	CcSEcCtD
Agomelatine—Abdominal pain—Hydrocortisone—psoriasis	0.00046	0.00104	CcSEcCtD
Agomelatine—Asthenia—Mycophenolate mofetil—psoriasis	0.000458	0.00103	CcSEcCtD
Agomelatine—Pruritus—Mycophenolate mofetil—psoriasis	0.000452	0.00102	CcSEcCtD
Agomelatine—Anxiety—Prednisone—psoriasis	0.00045	0.00101	CcSEcCtD
Agomelatine—Insomnia—Dexamethasone—psoriasis	0.00045	0.00101	CcSEcCtD
Agomelatine—Insomnia—Betamethasone—psoriasis	0.00045	0.00101	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000449	0.00101	CcSEcCtD
Agomelatine—Diarrhoea—Cyclosporine—psoriasis	0.000448	0.00101	CcSEcCtD
Agomelatine—Paraesthesia—Dexamethasone—psoriasis	0.000446	0.001	CcSEcCtD
Agomelatine—Paraesthesia—Betamethasone—psoriasis	0.000446	0.001	CcSEcCtD
Agomelatine—Mental disorder—Methotrexate—psoriasis	0.000446	0.001	CcSEcCtD
Agomelatine—MTNR1B—Circadian rythm related genes—NOS2—psoriasis	0.00044	0.00939	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—NOS2—psoriasis	0.00044	0.00939	CbGpPWpGaD
Agomelatine—Dyspepsia—Betamethasone—psoriasis	0.000438	0.000985	CcSEcCtD
Agomelatine—Dyspepsia—Dexamethasone—psoriasis	0.000438	0.000985	CcSEcCtD
Agomelatine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000437	0.000984	CcSEcCtD
Agomelatine—Urticaria—Triamcinolone—psoriasis	0.000435	0.00098	CcSEcCtD
Agomelatine—Dizziness—Cyclosporine—psoriasis	0.000433	0.000975	CcSEcCtD
Agomelatine—Infection—Prednisone—psoriasis	0.00043	0.000968	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000429	0.000966	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000429	0.000966	CcSEcCtD
Agomelatine—Back pain—Methotrexate—psoriasis	0.000429	0.000965	CcSEcCtD
Agomelatine—Fatigue—Dexamethasone—psoriasis	0.000429	0.000965	CcSEcCtD
Agomelatine—Fatigue—Betamethasone—psoriasis	0.000429	0.000965	CcSEcCtD
Agomelatine—Nervous system disorder—Prednisone—psoriasis	0.000425	0.000956	CcSEcCtD
Agomelatine—Dizziness—Mycophenolate mofetil—psoriasis	0.000422	0.000951	CcSEcCtD
Agomelatine—Skin disorder—Prednisone—psoriasis	0.000421	0.000947	CcSEcCtD
Agomelatine—Hyperhidrosis—Prednisone—psoriasis	0.000419	0.000942	CcSEcCtD
Agomelatine—Vision blurred—Methotrexate—psoriasis	0.000418	0.00094	CcSEcCtD
Agomelatine—Asthenia—Hydrocortisone—psoriasis	0.000418	0.00094	CcSEcCtD
Agomelatine—Vomiting—Cyclosporine—psoriasis	0.000416	0.000937	CcSEcCtD
Agomelatine—Pruritus—Hydrocortisone—psoriasis	0.000412	0.000927	CcSEcCtD
Agomelatine—MTNR1A—Circadian rythm related genes—PPARG—psoriasis	0.000412	0.00878	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—PPARG—psoriasis	0.000412	0.00878	CbGpPWpGaD
Agomelatine—Headache—Cyclosporine—psoriasis	0.00041	0.000923	CcSEcCtD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000409	0.00873	CbGpPWpGaD
Agomelatine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000407	0.000915	CcSEcCtD
Agomelatine—Gastrointestinal pain—Betamethasone—psoriasis	0.000407	0.000915	CcSEcCtD
Agomelatine—Vomiting—Mycophenolate mofetil—psoriasis	0.000406	0.000914	CcSEcCtD
Agomelatine—Headache—Mycophenolate mofetil—psoriasis	0.0004	0.000901	CcSEcCtD
Agomelatine—Vertigo—Methotrexate—psoriasis	0.000398	0.000897	CcSEcCtD
Agomelatine—Diarrhoea—Hydrocortisone—psoriasis	0.000398	0.000896	CcSEcCtD
Agomelatine—Urticaria—Dexamethasone—psoriasis	0.000395	0.000889	CcSEcCtD
Agomelatine—Urticaria—Betamethasone—psoriasis	0.000395	0.000889	CcSEcCtD
Agomelatine—Dizziness—Prednisolone—psoriasis	0.000394	0.000887	CcSEcCtD
Agomelatine—Asthenia—Triamcinolone—psoriasis	0.000393	0.000885	CcSEcCtD
Agomelatine—Abdominal pain—Betamethasone—psoriasis	0.000393	0.000885	CcSEcCtD
Agomelatine—Abdominal pain—Dexamethasone—psoriasis	0.000393	0.000885	CcSEcCtD
Agomelatine—Insomnia—Prednisone—psoriasis	0.000392	0.000881	CcSEcCtD
Agomelatine—Nausea—Cyclosporine—psoriasis	0.000389	0.000875	CcSEcCtD
Agomelatine—Paraesthesia—Prednisone—psoriasis	0.000389	0.000875	CcSEcCtD
Agomelatine—Pruritus—Triamcinolone—psoriasis	0.000388	0.000873	CcSEcCtD
Agomelatine—HTR2B—GPCR ligand binding—HCAR2—psoriasis	0.000386	0.00824	CbGpPWpGaD
Agomelatine—Dizziness—Hydrocortisone—psoriasis	0.000385	0.000866	CcSEcCtD
Agomelatine—Dyspepsia—Prednisone—psoriasis	0.000381	0.000858	CcSEcCtD
Agomelatine—Nausea—Mycophenolate mofetil—psoriasis	0.000379	0.000854	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000375	0.000844	CcSEcCtD
Agomelatine—Fatigue—Prednisone—psoriasis	0.000373	0.00084	CcSEcCtD
Agomelatine—Headache—Prednisolone—psoriasis	0.000373	0.00084	CcSEcCtD
Agomelatine—Constipation—Prednisone—psoriasis	0.00037	0.000833	CcSEcCtD
Agomelatine—Vomiting—Hydrocortisone—psoriasis	0.00037	0.000833	CcSEcCtD
Agomelatine—Headache—Hydrocortisone—psoriasis	0.000365	0.000821	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—HCAR2—psoriasis	0.000363	0.00773	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HCAR2—psoriasis	0.000363	0.00773	CbGpPWpGaD
Agomelatine—Dizziness—Triamcinolone—psoriasis	0.000362	0.000816	CcSEcCtD
Agomelatine—Infection—Methotrexate—psoriasis	0.00036	0.000809	CcSEcCtD
Agomelatine—Asthenia—Dexamethasone—psoriasis	0.000357	0.000803	CcSEcCtD
Agomelatine—Asthenia—Betamethasone—psoriasis	0.000357	0.000803	CcSEcCtD
Agomelatine—Nervous system disorder—Methotrexate—psoriasis	0.000355	0.000799	CcSEcCtD
Agomelatine—Gastrointestinal pain—Prednisone—psoriasis	0.000354	0.000797	CcSEcCtD
Agomelatine—Nausea—Prednisolone—psoriasis	0.000354	0.000797	CcSEcCtD
Agomelatine—Pruritus—Dexamethasone—psoriasis	0.000352	0.000792	CcSEcCtD
Agomelatine—Pruritus—Betamethasone—psoriasis	0.000352	0.000792	CcSEcCtD
Agomelatine—Skin disorder—Methotrexate—psoriasis	0.000352	0.000791	CcSEcCtD
Agomelatine—MTNR1B—GPCR downstream signaling—CCL20—psoriasis	0.000351	0.00749	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—CCL20—psoriasis	0.000351	0.00749	CbGpPWpGaD
Agomelatine—Hyperhidrosis—Methotrexate—psoriasis	0.00035	0.000787	CcSEcCtD
Agomelatine—Vomiting—Triamcinolone—psoriasis	0.000348	0.000784	CcSEcCtD
Agomelatine—Nausea—Hydrocortisone—psoriasis	0.000346	0.000778	CcSEcCtD
Agomelatine—Urticaria—Prednisone—psoriasis	0.000344	0.000774	CcSEcCtD
Agomelatine—Headache—Triamcinolone—psoriasis	0.000343	0.000773	CcSEcCtD
Agomelatine—Abdominal pain—Prednisone—psoriasis	0.000342	0.00077	CcSEcCtD
Agomelatine—Diarrhoea—Dexamethasone—psoriasis	0.00034	0.000766	CcSEcCtD
Agomelatine—Diarrhoea—Betamethasone—psoriasis	0.00034	0.000766	CcSEcCtD
Agomelatine—Dizziness—Betamethasone—psoriasis	0.000329	0.00074	CcSEcCtD
Agomelatine—Dizziness—Dexamethasone—psoriasis	0.000329	0.00074	CcSEcCtD
Agomelatine—Insomnia—Methotrexate—psoriasis	0.000327	0.000737	CcSEcCtD
Agomelatine—Nausea—Triamcinolone—psoriasis	0.000326	0.000733	CcSEcCtD
Agomelatine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000325	0.00693	CbGpPWpGaD
Agomelatine—Paraesthesia—Methotrexate—psoriasis	0.000325	0.000731	CcSEcCtD
Agomelatine—Somnolence—Methotrexate—psoriasis	0.000322	0.000724	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—CCL20—psoriasis	0.000319	0.0068	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—CCL20—psoriasis	0.000319	0.0068	CbGpPWpGaD
Agomelatine—Dyspepsia—Methotrexate—psoriasis	0.000319	0.000717	CcSEcCtD
Agomelatine—Vomiting—Dexamethasone—psoriasis	0.000316	0.000711	CcSEcCtD
Agomelatine—Vomiting—Betamethasone—psoriasis	0.000316	0.000711	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—TAGAP—psoriasis	0.000314	0.00671	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TAGAP—psoriasis	0.000314	0.00671	CbGpPWpGaD
Agomelatine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000312	0.000703	CcSEcCtD
Agomelatine—Fatigue—Methotrexate—psoriasis	0.000312	0.000702	CcSEcCtD
Agomelatine—HTR2C—GPCR ligand binding—HCAR2—psoriasis	0.000312	0.00664	CbGpPWpGaD
Agomelatine—Headache—Betamethasone—psoriasis	0.000311	0.000701	CcSEcCtD
Agomelatine—Headache—Dexamethasone—psoriasis	0.000311	0.000701	CcSEcCtD
Agomelatine—Asthenia—Prednisone—psoriasis	0.000311	0.000699	CcSEcCtD
Agomelatine—Pruritus—Prednisone—psoriasis	0.000306	0.000689	CcSEcCtD
Agomelatine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000305	0.0065	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000301	0.00641	CbGpPWpGaD
Agomelatine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000296	0.00632	CbGpPWpGaD
Agomelatine—Diarrhoea—Prednisone—psoriasis	0.000296	0.000667	CcSEcCtD
Agomelatine—Gastrointestinal pain—Methotrexate—psoriasis	0.000296	0.000666	CcSEcCtD
Agomelatine—Nausea—Dexamethasone—psoriasis	0.000295	0.000665	CcSEcCtD
Agomelatine—Nausea—Betamethasone—psoriasis	0.000295	0.000665	CcSEcCtD
Agomelatine—MTNR1A—Circadian rythm related genes—JUN—psoriasis	0.000292	0.00623	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—JUN—psoriasis	0.000292	0.00623	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00029	0.00619	CbGpPWpGaD
Agomelatine—Urticaria—Methotrexate—psoriasis	0.000287	0.000647	CcSEcCtD
Agomelatine—Dizziness—Prednisone—psoriasis	0.000286	0.000644	CcSEcCtD
Agomelatine—Abdominal pain—Methotrexate—psoriasis	0.000286	0.000644	CcSEcCtD
Agomelatine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000278	0.00593	CbGpPWpGaD
Agomelatine—MTNR1B—G alpha (i) signalling events—CXCL8—psoriasis	0.000277	0.00591	CbGpPWpGaD
Agomelatine—MTNR1A—G alpha (i) signalling events—CXCL8—psoriasis	0.000277	0.00591	CbGpPWpGaD
Agomelatine—Vomiting—Prednisone—psoriasis	0.000275	0.00062	CcSEcCtD
Agomelatine—Headache—Prednisone—psoriasis	0.000271	0.00061	CcSEcCtD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000263	0.00562	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.00026	0.00556	CbGpPWpGaD
Agomelatine—Asthenia—Methotrexate—psoriasis	0.00026	0.000584	CcSEcCtD
Agomelatine—Nausea—Prednisone—psoriasis	0.000257	0.000579	CcSEcCtD
Agomelatine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000257	0.00548	CbGpPWpGaD
Agomelatine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000256	0.00547	CbGpPWpGaD
Agomelatine—Pruritus—Methotrexate—psoriasis	0.000256	0.000576	CcSEcCtD
Agomelatine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000253	0.00539	CbGpPWpGaD
Agomelatine—Diarrhoea—Methotrexate—psoriasis	0.000248	0.000557	CcSEcCtD
Agomelatine—Dizziness—Methotrexate—psoriasis	0.000239	0.000539	CcSEcCtD
Agomelatine—Vomiting—Methotrexate—psoriasis	0.00023	0.000518	CcSEcCtD
Agomelatine—Headache—Methotrexate—psoriasis	0.000227	0.00051	CcSEcCtD
Agomelatine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000227	0.00483	CbGpPWpGaD
Agomelatine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000225	0.00479	CbGpPWpGaD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00022	0.0047	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00022	0.0047	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—HCAR2—psoriasis	0.000218	0.00465	CbGpPWpGaD
Agomelatine—Nausea—Methotrexate—psoriasis	0.000215	0.000484	CcSEcCtD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000212	0.00453	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CCL20—psoriasis	0.000201	0.00428	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HCAR2—psoriasis	0.000198	0.00423	CbGpPWpGaD
Agomelatine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000194	0.00413	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—TP53—psoriasis	0.000193	0.00411	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TP53—psoriasis	0.000193	0.00411	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCL20—psoriasis	0.000188	0.00402	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCL20—psoriasis	0.000188	0.00402	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—IL6—psoriasis	0.000176	0.00376	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—IL6—psoriasis	0.000176	0.00376	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	0.000176	0.00375	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—CXCL8—psoriasis	0.000168	0.00358	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—CXCL8—psoriasis	0.000168	0.00358	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CCL20—psoriasis	0.000162	0.00345	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HCAR2—psoriasis	0.00016	0.00341	CbGpPWpGaD
Agomelatine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.00015	0.0032	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000125	0.00266	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HCAR2—psoriasis	0.000117	0.0025	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CCL20—psoriasis	0.000113	0.00242	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.00011	0.00235	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000108	0.0023	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000104	0.00221	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SOCS1—psoriasis	0.000104	0.00221	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SOCS1—psoriasis	0.000104	0.00221	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CCL20—psoriasis	0.000103	0.0022	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TAGAP—psoriasis	0.000101	0.00216	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—TYK2—psoriasis	9.89e-05	0.00211	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—TYK2—psoriasis	9.89e-05	0.00211	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—CXCL8—psoriasis	9.48e-05	0.00202	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—CXCL8—psoriasis	9.48e-05	0.00202	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HCAR2—psoriasis	9.44e-05	0.00201	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	9.42e-05	0.00201	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CCL20—psoriasis	9.14e-05	0.00195	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	8.9e-05	0.0019	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—CXCL8—psoriasis	8.61e-05	0.00184	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—CXCL8—psoriasis	8.61e-05	0.00184	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CCL20—psoriasis	8.3e-05	0.00177	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TAGAP—psoriasis	8.19e-05	0.00175	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.08e-05	0.00172	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	8.08e-05	0.00172	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—APOE—psoriasis	7.65e-05	0.00163	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—APOE—psoriasis	7.65e-05	0.00163	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—LEP—psoriasis	7.65e-05	0.00163	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—LEP—psoriasis	7.65e-05	0.00163	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NFKBIA—psoriasis	7.13e-05	0.00152	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NFKBIA—psoriasis	7.13e-05	0.00152	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.11e-05	0.00152	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NDUFA5—psoriasis	6.13e-05	0.00131	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCL20—psoriasis	6.08e-05	0.0013	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TYK2—psoriasis	5.84e-05	0.00125	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TYK2—psoriasis	5.84e-05	0.00125	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.74e-05	0.00122	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.72e-05	0.00122	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CXCL8—psoriasis	5.42e-05	0.00116	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.4e-05	0.00115	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NDUFA5—psoriasis	5.24e-05	0.00112	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP2S1—psoriasis	5.21e-05	0.00111	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CXCL8—psoriasis	5.09e-05	0.00108	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CXCL8—psoriasis	5.09e-05	0.00108	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCL20—psoriasis	4.91e-05	0.00105	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.88e-05	0.00104	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL6—psoriasis	4.84e-05	0.00103	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL6—psoriasis	4.84e-05	0.00103	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—JUN—psoriasis	4.73e-05	0.00101	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—JUN—psoriasis	4.73e-05	0.00101	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NFKB1—psoriasis	4.55e-05	0.000971	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NFKB1—psoriasis	4.55e-05	0.000971	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2S1—psoriasis	4.45e-05	0.00095	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CXCL8—psoriasis	4.37e-05	0.000932	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.35e-05	0.000928	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—VEGFA—psoriasis	4.13e-05	0.000881	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—VEGFA—psoriasis	4.13e-05	0.000881	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—STAT3—psoriasis	4.09e-05	0.000872	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—STAT3—psoriasis	4.09e-05	0.000872	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SOCS1—psoriasis	3.35e-05	0.000714	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—TYK2—psoriasis	3.19e-05	0.000681	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—psoriasis	3.12e-05	0.000666	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—psoriasis	3.12e-05	0.000666	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	3.06e-05	0.000653	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL6—psoriasis	2.86e-05	0.000609	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL6—psoriasis	2.86e-05	0.000609	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CXCL8—psoriasis	2.78e-05	0.000593	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.73e-05	0.000583	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SOCS1—psoriasis	2.7e-05	0.000576	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—TYK2—psoriasis	2.58e-05	0.000549	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CARM1—psoriasis	2.55e-05	0.000543	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—LEP—psoriasis	2.47e-05	0.000527	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APOE—psoriasis	2.47e-05	0.000527	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	2.47e-05	0.000527	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.38e-05	0.000508	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.33e-05	0.000498	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NFKBIA—psoriasis	2.3e-05	0.000491	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CXCL8—psoriasis	2.24e-05	0.000478	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CARM1—psoriasis	2.18e-05	0.000464	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.03e-05	0.000434	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LEP—psoriasis	1.99e-05	0.000425	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APOE—psoriasis	1.99e-05	0.000425	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TYK2—psoriasis	1.89e-05	0.000402	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	1.86e-05	0.000396	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CXCL8—psoriasis	1.64e-05	0.00035	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CAT—psoriasis	1.57e-05	0.000334	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—psoriasis	1.56e-05	0.000333	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JUN—psoriasis	1.53e-05	0.000326	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TYK2—psoriasis	1.52e-05	0.000324	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NFKB1—psoriasis	1.47e-05	0.000313	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CAT—psoriasis	1.34e-05	0.000285	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—psoriasis	1.33e-05	0.000284	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CXCL8—psoriasis	1.32e-05	0.000283	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—psoriasis	1.32e-05	0.000282	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—psoriasis	1.26e-05	0.000269	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JUN—psoriasis	1.23e-05	0.000263	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—APOE—psoriasis	1.22e-05	0.000259	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NFKB1—psoriasis	1.19e-05	0.000253	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—psoriasis	1.08e-05	0.000229	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—psoriasis	1.07e-05	0.000227	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARG—psoriasis	1.06e-05	0.000226	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—APOE—psoriasis	1.04e-05	0.000222	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—psoriasis	1.01e-05	0.000215	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—psoriasis	9.22e-06	0.000197	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARG—psoriasis	9.06e-06	0.000193	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—psoriasis	8.13e-06	0.000173	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—psoriasis	7.44e-06	0.000159	CbGpPWpGaD
